Thursday, July 9, 2026

Patent intelligence · US

US 7332585

Bispecific single chain Fv antibody molecules and methods of use thereof

granted A61KA61K2039/505A61K39/395A61K51/109
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 2
Applicant portfolio 8,292
Patent details — US 7332585
Jurisdiction
US
Status
granted
Grant date
Feb 19, 2008
Expiration
Feb 14, 2028
Claims
13
CPC classes
A61K, A61K2039/505, A61K39/395, A61K51/109
View on Google Patents ↗

Quick answer

US 7332585 (Bispecific single chain Fv antibody molecules and methods of use thereof) is held by The Regents of the California University. Status: granted. Granted Feb 19, 2008. Expires Feb 14, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
13
CPC classes
A61K, A61K2039/505, A61K39/395, A61K51/109, A61P, A61P31/00

More from The Regents of the California University

Related pharmaceutical patents in our USPTO index.

  1. US 12428463

    Chimeric antigen receptors targeting abnormal glycobiology

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Expires Sep 25, 2045

    granted
  2. US 12427148

    Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  3. US 12428416

    ERK inhibitors and uses thereof

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  4. US 12427151

    Compositions and method of treating cancer

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  5. US 12427197

    Methods of producing cobalt nanoparticles and hollow metal nanospheres

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  6. US 12428489

    Human PD-L2 antibodies and methods of use therefor

    The Board of Regents of the University of Texas System · Expires Sep 25, 2045

    granted
  7. US 12427155

    Treatment for tau-related diseases

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  8. US 12428455

    Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells

    The Regents of the University of California · Expires Sep 25, 2045

    granted

Frequently asked questions

What is US patent 7332585?

US 7332585 (Bispecific single chain Fv antibody molecules and methods of use thereof) is held by The Regents of the California University. Status: granted. Granted Feb 19, 2008. Expires Feb 14, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 7332585?

The Regents of the California University is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.

When does US 7332585 expire?

Our index shows an expiration date of Feb 14, 2028 (2 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.